A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
Phase 2
Active, not recruiting
NCT04640623
| Condition | Urinary Bladder Neoplasms |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Janssen Research & Development, LLC |
|---|
| Status | Active, not recruiting |
|---|
| Enrollment | 220 participants |
|---|
| Interventions | TAR-200, Cetrelimab |
|---|
| Start date | Dec 18, 2020 |
|---|
| Completion date | Jul 3, 2025 |
|---|
| Results posted | Jul 29, 2026 |
|---|
Summary
The purpose of this study is to evaluate the overall complete response (CR) rate in participants treated with TAR-200 in combination with cetrelimab (Cohort 1), or TAR-200 alone (Cohort 2), or cetrelimab alone (Cohort 3) with Carcinoma in Situ (CIS), with or without concomitant high-grade Ta or T1 papillary disease; and disease-free survival (DFS) in participants treated with TAR-200 alone with papillary disease only (Cohort 4).
Cohorts 1, 2, and 3: Overall Complete Response (CR) Rate
From date of first dose up to clinical cut-off date 3rd July 2025 (up to 50 months) · percentage of participants
| Cohort 1: TAR-200 + Cetrelimab (CIS With or Without Papillary Disease) | 67.9 percentage of participants |
|---|
| Cohort 2: TAR-200 Monotherapy (CIS With or Without Papillary Disease) | 82.4 percentage of participants |
|---|
| Cohort 3: Cetrelimab IV Monotherapy (CIS With or Without Papillary Disease) | 46.4 percentage of participants |
|---|
Cohort 4: Disease-free Survival (DFS)
From date of first dose up to clinical cut-off date 3rd July 2025 (up to 50 months) · months
| Cohort 4: TAR-200 Monotherapy (Papillary Disease Only) | NA months |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.